(Q38053481)

27 August 2017

The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. (English)

1 reference

27 August 2017

1 reference

acute coronary syndrome

1 reference

inferred from title

author name string

Dominick J Angiolillo

series ordinal

1

1 reference

27 August 2017

1 November 2012

1 reference

27 August 2017

1 reference

27 August 2017

72

1 reference

27 August 2017

16

1 reference

27 August 2017

2087-2116

1 reference

https://scigraph.springernature.com/pub.10.2165/11640880-000000000-00000

27 August 2017

0 references

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Associ

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Clinical aspects of platelet inhibitors and thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Cell adhesion mechanisms in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Central role of the P2Y12 receptor in platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Activation of platelet function through G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Protease-activated receptors in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Basic principles of platelet biology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Clinical importance of aspirin and clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Variability in responsiveness to oral antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Impact of medication therapy discontinuation on mortality after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Aspirin resistance an underestimated risk in patients with drug-eluting stents?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Aspirin and clopidogrel resistance: methodological challenges and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Aspirin resistance and compliance with therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Aspirin dose for the prevention of cardiovascular disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Biology and pharmacology of the platelet P2Y12 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Identification of the active metabolite of ticlopidine from rat in vitro metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Clopidogrel-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Platelet function testing and risk of bleeding complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Should clopidogrel be stopped prior to urgent cardiac surgery?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

The pharmacogenetics of antiplatelet agents: towards personalized therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Allergic reactions to clopidogrel and cross-reactivity to other agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Early versus delayed, provisional eptifibatide in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Cangrelor: a review on its mechanism of action and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Elinogrel: pharmacological principles, preclinical and early phase clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Ear

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Platelet thrombin receptor antagonism and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Vorapaxar in the secondary prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

New directions in antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Therapeutic potentials of sarpogrelate in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640880-000000000-00000

Pharmacokinetic profile of 14C-labeled clopidogrel

21 January 2018

1 reference

12 December 2020

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

1 reference

12 December 2020

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II

1 reference

12 December 2020

Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations

1 reference

12 December 2020

Impaired platelet-connective-tissue reaction in man after aspirin ingestion

1 reference

12 December 2020

Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition.

1 reference

12 December 2020

Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention

1 reference

12 December 2020

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

12 December 2020

Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease

1 reference

12 December 2020

Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine

1 reference

12 December 2020

High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes

1 reference

12 December 2020

Eptifibatide: The evidence for its role in the management of acute coronary syndromes

1 reference

12 December 2020

Paraoxonase-1 is a major determinant of clopidogrel efficacy

1 reference

12 December 2020

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

1 reference

12 December 2020

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

12 December 2020

Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes

1 reference

12 December 2020

Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial

1 reference

12 December 2020

Dose-dependent influence of acetylsalicyclic acid on platelet functions and plasmatic coagulation factors

1 reference

12 December 2020

Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden.

1 reference

12 December 2020

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study

1 reference

12 December 2020

The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation

1 reference

12 December 2020

Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies

1 reference

12 December 2020

Increased blood fibrinolytic activity after aspirin ingestion

1 reference

12 December 2020

Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Ticlopidine versus oral anticoagulation for coronary stenting

1 reference

12 December 2020

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

1 reference

12 December 2020

Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects

1 reference

12 December 2020

Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions

1 reference

12 December 2020

RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2

1 reference

12 December 2020

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

1 reference

12 December 2020

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

1 reference

12 December 2020

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patie

1 reference

12 December 2020

10.2165/11640880-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

23083110

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

23083110